Lightcast Secures $27M to Boost Envisia™ Platform Commercialisation

Lightcast, known for its innovative functional single-cell analysis tools, has successfully raised $27 million in a funding round, led by ARCH Venture Partners, with participation from M Ventures, Illumina Ventures, and others. The capital infusion aims to propel the commercialisation of Lightcast’s Envisia™ platform, anticipated for a full market release in 2026. This financial boost underscores the platform’s potential impact on the biotechnology sector, particularly in therapies and drug development.

Operating at the intersection of cutting-edge technology and life sciences, Lightcast’s Envisia™ platform is set to disrupt traditional single-cell analysis by offering direct measurement of cell function. Unlike conventional methods that rely on genetic inferences, Envisia™ uses light-controlled droplet manipulation to provide real-time, functional cellular analysis. This approach is set to accelerate processes in antibody discovery, oncology therapeutics, and cell line development. During its early access phase, the platform has shown promising results in collaboration with pharmaceutical giants and academic scholars, positioning Lightcast as a significant player in the life sciences.

To further steer its commercialisation journey, Lightcast has appointed industry expert Brad Crutchfield as an advisor. With vast experience scaling innovative single-cell technologies, Crutchfield’s insights are expected to guide Lightcast’s global expansion efforts. His addition reinforces Lightcast’s commitment to revolutionising single-cell analysis, making functional cellular insights more accessible and expediting the path from research to therapeutic development.